Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GSK256073A tablets
GSK256073A · 3 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| GSK256073A tablets + IR niacin tablets | DRUG | single dosing for 4 to 5 sessions |
| GSK256073A tablets | DRUG | - |
Inclusion Criteria: * Adult males between 18 and 55 years of age, inclusive. * Healthy subjects * Body weight \> 50 kg (110 pounds) and body mass index (BMI) between 19 and 31 where: * Subjects with QTc \< 450 msec at screening Exclusion Criteria: * History of significant cardiac arrhythmias * Ac...
GSK256073A is an investigational small molecule developed by GSK plc for dyslipidaemias, a group of lipid disorders. It has been studied in Phase 1 clinical trials, including research into whether it can block niacin-induced flushing in healthy volunteers. It is not an approved medicine.
GSK256073A is being investigated for dyslipidaemias, conditions marked by abnormal lipid levels in the blood. Its Phase 1 program also evaluated whether the compound could block niacin-induced flushing in healthy volunteers. It remains an investigational agent and is not approved for any use.
GSK256073A is developed by GSK plc, which trades under the ticker GSK. The company sponsored all three Phase 1 trials of the compound, which were conducted in the United States in healthy volunteers.
GSK256073A is in Phase 1 development. All three of its clinical trials are Phase 1 studies and all three are completed, with no active trials ongoing. The compound is investigational and has not been approved for marketing.
GSK256073A has been studied in three completed Phase 1 trials: NCT00608699, which tested whether it blocks niacin-induced flushing in 24 healthy male volunteers; NCT00551694, a second study in healthy volunteers with 4 participants; and NCT00488449, a pharmacokinetics and pharmacodynamics study with 56 participants. All were conducted in the United States.